Current treatment of non-metastatic castration-refractory prostate cancer

Česká verzia

Authors: Tomáš Büchler
Authors place of work: Onkologická klinika 1. LF UK a FTN Praha
Published in the journal: Klin Onkol 2021; 34(3): 185-191
Category: Review
doi: https://doi.org/10.48095/ccko2021185

Summary

Background: Non-metastatic castration-refractory prostate cancer (nmCRPC) is defined by increasing serum prostate specific antigen (PSA) levels despite androgen deprivation therapy in the absence of metastases on standard imaging methods including CT of the chest, abdomen and pelvis, and bone scan. Patients with nmCRPC and short PSA doubling time (PSAdt) are at high risk of developing early metastatic disease. Objectives: The objective of this review is to summarize current data on the treatment of nmCRPC. The current data support the efficacy of three novel androgen receptor targeted agents (ARTA), darolutamide, apalutamide and enzalutamide. Conclusions: The design and eligibility criteria of the three key studies with darolutamide, apalutamide and enzalutamide were similar. Patients were required to have a PSAdt < 10 months. The study allowed the participation of patients with local lymphadenopathy (below the aortic bifurcation level) of < 2 cm in the ARAMIS (darolutamide) and SPARTAN (apalutamide) studies and < 1.5 cm in the PROSPER (enzalutamide) study. All of these studies have shown prolongation of metastasis-free survival as well as improved overall survival in the active arms. Prolonging the time to metastasis in patients with nmCRPC is an important therapeutic objective in itself, as skeletal metastases are associated with disease symptoms, such as bone pain. The evidence of extended survival reinforces the indication of ARTA in nmCRPC therapy. The early inclusion of ARTA in the treatment algorithms for prostate cancer raises questions about sequencing of subsequent systemic therapies. The use of advanced imaging methods such as PET using a labeled prostate specific membrane antigen ligand is also discussed. However, according to the current consensus, the findings of distant metastases using these next-generation imaging methods do not change the diagnosis of nmCRPC, if no distant lesions are detected by conventional staging.

Keywords:

castration-refractory prostate cancer – androgen antagonists – antineoplastic agents – drug toxicity – survival

Zdroje

Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. [online]. Dostupné z: http/ / www.svod.cz. 2005.
Krejčí D, Svobodová I, Pehalová L et al. Novotvary. [online]. Dostupné z: https:/ / www.uzis.cz/ index.php?pg=record&id=8352.
Dusek L, Muzik J, Maluskova D et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2014; 27(6): 406–423. doi: 10.14735/ amko2014406.
Fendler WP, Weber M, Iravani A et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 2019; 25(24): 7448–7454. doi: 10.1158/ 1078-0432.CCR-19-1050.
Scher HI, Solo K, Valant J et al. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One 2015; 10(10): e0139440. doi: 10.1371/ journal.pone.0139440.
Hussain M, Fizazi K, Saad F et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018; 378(26): 2465–2474. doi: 10.1056/ NEJMoa1800536.
Fizazi K, Shore N, Tammela TL et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019; 380(13): 1235–1246. doi: 10.1056/ NEJMoa1815671.
Smith MR, Saad F, Chowdhury S et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018; 378(15): 1408–1418. doi: 10.1056/ NEJMoa1715546.
Afshar M, Evison F, James ND et al. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: a tertiary academic center experience. Urol Oncol 2015; 33(8): 338. doi: 10.1016/ j.urolonc.2015.05.003.
Smith MR, Saad F, Oudard S et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013; 31(30): 3800–3806. doi: 10.1200/ JCO.2012.44.6716.
Luo J, Beer TM, Graff JN. Treatment of nonmetastatic castration-resistant prostate cancer. Oncology (Williston Park) 2016; 30(4): 336–344.
Saad F, Bögemann M, Suzuki K et al. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. Prostate Cancer Prostatic Dis 2021. [in press]. doi: 10.1038/ s41391-020-00310-3.
Sternberg CN, Fizazi K, Saad F et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2020; 382(23): 2197–2106. doi: 10.1056/ NEJMoa2003892.
Fizazi K, Shore N, Tammela TL et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020; 383(11): 1040–1049. doi: 10.1056/ NEJMoa2001342.
Smith MR, Saad F, Chowdhury S et al. Apalutamide and overall survival in prostate cancer. Eur Urol 2021; 79(1): 150–158. doi: 10.1093/ annonc/ mdz397.
Di Nunno V, Mollica V, Santoni M et al. New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes. Clin Genitourin Cancer 2019; 17(5): e871–e877. doi: 10.1016/ j.clgc.2019.07.001.
Lu-Yao G, Nikita N, Keith SW et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol 2020; 77(2): 158–166. doi: 10.1016/ j.eururo.2019.07. 031.
Levine GN, D’Amico AV, Berger P et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010; 121(6): 833–840. doi: 10.1161/ CIRCULATIONAHA.109.192695.
Bhatia N, Santos M, Jones LW et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation 2016;133(5): 537–541. doi: 10.1161/ CIRCULATIONAHA.115.012519.
Scher HI, Morris MJ, Stadler WM et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016; 34(12): 1402–1418. doi: 10.1200/ JCO.2015.64.2702.
https:/ / www.mskcc.org/ nomograms/ prostate/ psa_doubling_time.
Fallah J, Zhang L, Weinstock C et al. An FDA pooled analysis: characteristics and outcomes of patients with nonmetastatic castration-resistant prostate cancer, based on prior history of prostatectomy and/ or radiation therapy. [online]. Available from: https:/ / doi.org/ 10.1200/ JCO.2021.39.6_suppl.197.
Anderson CB, Pyle AL, Woodworth A et al. Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies. Prostate Cancer Prostatic Dis 2012; 15(2): 182–188. doi: 10.1038/ pcan.2011.58.
Mori K, Miura N, Mostafaei H et al. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2020; 23(4): 539–548. doi: 10.1038/ s41391-020-0222-6.
de Wit R, de Bono J, Sternberg CN et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019; 381(26): 2506–2518. doi: 10.1056/ NEJMoa1911206.
National Comprehensive Cancer Network. Prostate cancer, version 2.2021. [online]. Available from: https:/ / www.nccn.org/ professionals/ physician_gls/ pdf/ prostate_blocks.pdf.
Schweizer MT, Antonarakis ES, Wang H et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med 2015; 7(269): 269ra2. doi: 10.1126/ scitranslmed.3010563.
Denmeade SR, Wang H, Agarwal N et al. TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer. J Clin Oncol 2021; 39(12): 1371–1382. doi: 10.1200/ JCO.20.02759.
Hofman MS, Lawrentschuk N, Francis RJ et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395(10231): 1208–1216. doi: 10.1016/ S0140-6736(20)30314-7.
EAU - EANM - ESTRO -ESUR - ISUP - SIOG guidelines on prostate cancer. [online]. Available from: https:/ / uroweb.org/ wp-content/ uploads/ EAU-EANM-ESTRO_ESUR_ISUP_SIOG-Guidelines-on-Prostate-Cancer.pdf.
Navrátil J, Poprach A, Lakomý R et al. Oligometastatic prostate cancer. Klin Onkol 2019; 32(2): 97–100. doi: 10.14735/ amko201997.
Franzese C, Di Brina L, D’Agostino G et al. Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis. J Cancer Res Clin Oncol 2019; 145(10): 2469–2479. doi: 10.1007/ s00432-019-03007-w.
Triggiani L, Alongi F, Buglione M et al. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 2017; 116(12): 1520–1525. doi: 10.1038/ bjc.2017.103.
Rogowski P, Roach M 3rd, Schmidt-Hegemann N-S et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol 2021; 16(1): 50. doi: 10.1186/ s13014-021-01776-8.
Phillips R, Shi WY, Deek M et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial. JAMA Oncol 2020; 6(5): 650–659. doi: 10.1001/ jamaoncol.2020.0147.